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Ⅰ．Introduction
 Autologous iliac crest bone grafting is considered 
the standard criterion for lumbar spinal fusion. However, 
the outcome of autograft use in lumbar spine fusion is 
associated with donor site morbidity, such as risk of 
infection, hematoma, fracture, wound healing problems, 
and donor site pain.［1-5］To avoid donor site problems 
relating to lumbar fusion, local bone, ceramics, 
demineralized bone matrix, and bone morphogenetic 
proteins （BMPs） have been used.［6］
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SUMMARY
Intermittent parathyroid hormone （PTH） treatment reduces the risk for osteoporotic vertebral 
fractures. Preclinical data support the efficacy of PTH for lumbar spinal fusion. However, few clinical 
results investigating PTH for spinal fusion have been reported.
We report a 67-year-old female patient with osteoporosis, rheumatoid arthritis, and diabetic 
mellitus, who underwent posterolateral fusion using local bone grafting. Blood serum showed high 
levels of bone resorption marker. The patient underwent primary lumbar surgery and two additional 
lumbar surgeries during one year. Primary surgery was decompression and posterolateral fusion using 
local bone grafting with pedicle screws, and the subsequent second and third surgeries were performed 
due to proximal and distal adjacent problems. To address risk factors relating to bone union, daily 
subcutaneous injection of teriparatide was prescribed for one year. Low back and leg pain scores 
improved after final surgery. The final fusion level was from T9 to iliac. A large posterolateral fusion 
mass was observed in the lumbar area. 
Daily subcutaneous injection of teriparatide using local bone grafting after instrumented lumbar 
posterolateral fusion was effective in a patient with risk factors for bone union.
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 Three studies （two retrospective and one prospective） 
have reported that local bone graft and iliac crest bone 
graft showed no significant differences in fusion rate for 
one level fusion.［7-9］However, limitations of local bone 
grafts compared to iliac crest bone grafts for multiple level 
fusions have been reported. Retrospective and prospective 
studies have shown that fusion rates were poor for local 
bone graft alone in cases of more than three levels.［7,10］
 Furthermore, many authors have reported risk 
factors that affect fusion in spine surgery including 
advanced age, sex, osteoporosis, smoking, diabetes 
mellitus, hypertension, revision surgery, multiple-level 
surgery, and medical comorbidities.［11,12］
 Intermittent administration of parathyroid hormone 
（PTH） increases bone mass and reduces the risk of 
osteoporotic vertebral fractures. Recombinant human 
PTH （1-34） has already been approved as a treatment 
for severe osteoporosis.［13］Preclinical data in animal 
models support the use of PTH for lumbar spinal 
fusion.［14-16］Only one report has shown that daily 
subcutaneous injection of PTH （teriparatide） for bone 
union using local bone grafting after instrumented 
lumbar posterolateral fusion in postmenopausal 
women with osteoporosis was more effective than oral 
administration of bisphosphonate.［17］
 In the current study, we report the clinical efficacy 
of teriparatide for bone union after instrumented lumbar 
posterolateral fusion using local bone grafting in a 
postmenopausal woman with risk factors for bone union 
such as osteoporosis, rheumatoid arthritis, and diabetic 
mellitus.
Ⅱ．Case
 The protocols for human procedures used in this 
study were approved by the ethics committee of our 
institution. Written, signed consent was received from 
the patient before treatment. 
 In March 2011, a 69-year-old woman presented with 
a 3-year history of bilateral sciatica with complaints 
of pain in her buttocks and the lateral aspects of her 
legs. There was no apparent motor weakness. Sensory 
examination confirmed hypoalgesia in the lateral aspect 
of her upper and lower leg corresponding to the L4 and 
L5 dermatome. Bilateral straight leg raising test results 
were negative. 
 The patient had osteoporosis, rheumatoid arthritis, 
and diabetes mellitus. Young adult mean bone mineral 
density was 68% using dual energy x-ray absorptiometry 
（DEXA）. The patient used 10mg of predonine for 
rheumatoid arthritis, and daily subcutaneous injection 
of insulin for diabetes mellitus. Laboratory data showed 
that white blood cell count was 7800/µl （normal range 
＜8000） and C-reactive protein was 1.8mg/dl （normal 
range ＜0.3）. Hemoglobin A1c was 7.2 （normal range 
＜5.8%）. The bone formation marker, bone alkaline 
phosphatase （BAP） was 6.0 （normal range: 7.9～
29.0U/L） and the bone resorption marker, cross-linked 
N-telopeptide of type I collagen （NTX） was 35.0 
（normal range: 7.5～16.5nmolBCE/L）. In order to 
reduce the risk factors that may affect bone union, daily 
subcutaneous injection of teriparatide was performed 
from 3 months before first surgery to 9 months after first 
surgery. 
 X-ray examination showed L2 retro-spondylolisthesis, 
and L3 and L4 anterior spondylolisthesis （Fig. 1）. 
MRI could not be performed due to her brain clipping; 
however, mylogram and CT after myelography 
showed spinal stenosis form L2-3 to L4-5 （Fig. 2）. As 
Fig. 1　 X-ray films showing thoracic and lumbar spine with 
osteoporosis. a: anterior-posterior view. b: profile 
view. 
ａ ｂ
9Teriparatide accelerates lumbar posterolateral fusion
conservative treatment was not effective, surgery was 
planned. We performed decompression from L2-3 to L4-5 
and posterolateral fusion with instrumentation at L2-L5. 
Local bone consisting of lamina and spinal processes at 
the decompressed site was used and bone morphogenetic 
protein was not used during surgery （Fig. 3）. The patient 
became symptom-free immediately after surgery, and the 
first 12 weeks post-operation were uneventful. However, 
the patient showed severe lower back and leg pain 12 
weeks after surgery, and myelogram showed an adjacent 
segment problem and severe instability at L1-L2 level 
（Fig. 4）. Therefore, in a second surgery we performed 
decompression at L1-2 with instrumentation at T9-L5. 
Local bone consisting of lamina and spinal processes was 
used for posterolateral and interbody fusion at L1-L2 （Fig. 
5）. The patient became symptom-free immediately again 
after surgery. However, the patient showed severe lower 
back and leg pain 6 weeks after the second surgery, and 
myelogram showed an adjacent lower segment problem 
and severe stenosis at L5-S1 level （Fig. 6）. Therefore, a 
third surgery was performed involving decompression at 
the L5-S1 level with addition of domino instrumentation 
to the iliac. Local bone from the L5-S1 level was used 
for posterolateral fusion at the L5-S1 level （Fig. 7）. On a 
follow-up examination, the patient was symptom-free, and 
daily subcutaneous injection of teriparatide was performed 
for 1 year （3 months before first surgery to 9 months after 
Fig. 2　 Mylogram and CT after myelography showed 
spinal stenosis form L2 -3  to L4 -5 ,  and L2 
retro- spondylolisthesis, and L3 and L4 anterior 
spondylolisthesis. a: anterior-posterior view. b: profile 
view. c: CT after myelography.
Fig. 4　 Myelogram showed upper adjacent segment problem 
and severe instability at L1-L2 level 3 months after 
first surgery. a: extended position. b: flexion position.
Fig. 3　 X-ray films after first surgery. Decompression 
from L2-3 to L4-5 and posterolateral fusion with 
instrumentation and local bone grafting was performed 
in the patient. a: anterior-posterior view. b: profile 
view. 
Fig. 5　 X-ray films after second surgery. Decompression at 
L1-2 with instrumentation and local bone grafting 
at T9-L5 was performed. a and b: anterior-posterior 
view. c and d: profile view.  
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first surgery）, and a large posterolateral fusion mass was 
observed.
Ⅲ．Discussion
 In this case report, a 67-year-old woman with 
osteoporosis, rheumatoid arthritis, and diabetic mellitus 
underwent posterolateral fusion using local bone 
grafting accompanied by daily subcutaneous injection 
of teriparatide for one year. After one year, a large 
posterolateral fusion mass was observed. 
 Many authors have reported that risk factors that 
affect fusion in spine surgery include advanced age, sex, 
osteoporosis, smoking, diabetes mellitus, hypertension, 
revision surgery, multiple-level surgery, and medical 
comorbidities.［11,12］Therefore, we considered this 
patient at particularly high risk for poor bone union 
before surgery. 
 Preclinical data support the use of parathyroid 
hormone for lumbar spinal fusion. Teriparatide was 
shown to enhance spinal fusion using an autogenous 
iliac crest bone graft in a rabbit model of posterolateral 
fusion.［14,15］Intermittent administration of PTH 
enhanced bone turnover predominantly on bone 
formation at the graft site, accelerating spinal fusion 
using autologous bone grafts in rats that underwent 
posterolateral fuison .［16］To our knowledge, two 
clinical trial using teriparatide were reported in 2010 and 
2011, respectively related to distal radial fractures and 
pelvic fractures.［18,19］Postmenopausal women, who 
had sustained a dorsally angulated distal radial fracture in 
need of closed reduction without surgery, were randomly 
assigned to eight weeks of once-daily injections of 
placebo or teriparatide.［18］The investigators concluded 
that healing time was shorter in the teriparatide-treated 
group.［18］In latter study, 65 elderly patients with 
osteoporosis had pelvic fractures. In this patient cohort, 
21 patients received a once-daily injection of 100 µg 
PTH 1-84 starting within two days after admission to 
the hospital, and 44 patients served as the control group. 
PTH 1-84 was observed to accelerate fracture-healing in 
pelvic fractures and improved the functional outcome. 
Only one article has reported efficacy of teriparatide for 
fracture healing in cervical spine.［20］Three patients 
were observed to develop painful delayed unions of type 
III odontoid fractures despite external immobilization. 
All three teriparatide-treated patients experienced both 
rapid clinical improvement and computed tomography 
evidence of fracture union.［20］
 The efficacy of daily subcutaneous injection of 
teriparatide for bone union using a local bone graft 
after instrumented lumbar posterolateral fusion in 
Fig. 6　 Myelogram showed lower adjacent segment problem 
（L5-S1） six weeks after second surgery. a: anterior-
posterior view. b: profile view.
Fig. 7　 Figures show X-ray film and CT 9 months after third 
surgery. Decompression at L5-S1 level with addition 
of domino instrumentation to iliac was performed. 
CT shows large bony mass at posterolateral region. 
a: anterior-posterior view. b: profile view. c: coronal 
plane of CT.
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follow-up. Spine 2011; 36: 1392-6. 
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model. Spine 2009; 34: 121-30.
16） Abe Y, Takahata M, Ito M, Irie K, Abumi K, Minami 
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postmenopausal women with osteoporosis has been 
reported.［17］Teriparatide-treated patients showed 
superior results for the rate and average duration of bone 
union compared with bisphosphonate-treated patients.
［17］However, the method of surgery was one-level 
or two-level posterolateral fusion.［17］In the current 
study, the patient had osteoporosis, rheumatoid arthritis, 
and diabetic mellitus, and underwent both primary 
lumbar surgery and two additional lumbar surgeries 
due to proximal and distal adjacent problems, and the 
final fusion level was from T9 to iliac. Bone resorption 
marker level was high in the patient. During surgery, 
we used only local bone. However, daily subcutaneous 
injection of teriparatide for 1 year enhanced large 
posterolateral fusion mass. Therefore, we concluded 
that combination of local bone and administration of 
teriparatide is useful for bone fusion in a patient with 
osteoporosis and some risk factors of non-union. The 
current study has limitations in that this is a single 
case report and the number of patients is restricted. 
Nevertheless, further studies are warranted into the 
efficacy of teriparatide to enhance spinal fusion in 
patients with osteoporosis. 
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